Recent advancements in single B cell screening technologies have transformed antibody discovery workflows. Traditional approaches include hybridoma technology and single B cell screening, which remain reliable. However, emergent technologies like LIBRA-seq and NanoPen platforms are improving the efficiency and scalability of antibody discovery processes.

The discovery of monoclonal antibodies (mAbs) for therapeutic and research applications has been a cornerstone of modern biotechnology. Two conventional approaches, hybridoma technology and single B cell screening, have historically driven the field, offering distinct strengths and limitations.

Image credit: Institute for ProteinIn the competitive landscape of antibody development, speed and precision are necessary. Traditional antibody discovery platforms—such as hybridoma and phage display—often have lengthytimelines to generate viable antibody candidates. However, Biointron’s A

Explore how single-cell antibody sequencing reveals immune diversity by analyzing individual B cells, offering precise insights into antibody repertoire & therapeutic discovery.

Explore groundbreaking high-throughput screening techniques, including phage display and microfluidics, advancing single B cell screening for therapeutic antibody discovery.

Discover how microfluidic technology in biotechnology is revolutionizing drug discovery, diagnostics & antibody screening. Learn more about its impact on precision medicine!

Explore advances in Single B Cell Screening, including microfluidics, deep sequencing & multiplexing, revolutionizing antibody discovery for infectious diseases. Learn more!

Learn how single B cell antibody technology accelerates antibody discovery with faster timelines, natural VH-VL pairing, & high-throughput screening for therapeutic innovation.

Explore Single B Cell Screening, a high-throughput technique for isolating antigen-specific mAbs, accelerating antibody discovery & therapeutic development. Learn more!

Biointron established a single-B cell antibody discovery platform based on microfluidic technology. Combined with our proprietary fast antibody expression platform, it has been proven to be fast and efficient in many projects.